EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.

People who take Leqembi and Kisunla are required to get an MRI brain scan once a quarter ... scan or to visit a healthcare provider. “The monitoring would need to be done either way, but if ...

LEQEMBI is indicated for the treatment of ... Monitoring and Dose Management Guidelines Baseline brain MRI and periodic monitoring with MRI are recommended. Enhanced clinical vigilance for ARIA ...

The European Medicines Agency (EMA) announced it will review new safety data on the Alzheimer’s disease drug Leqembi (lecanemab). This follows a prior decision to recommend its use in the ...

It’s unknown at this time what net price VHA will be paying for the drug. Leqembi’s annual list price is $26,500. But based on past experience the VHA has been able to extract significant ...

1,2,3 Only LEQEMBI works to fight AD in two ways: continuously clearing protofibrils and rapidly clearing plaque. This is important because with continuous administration, LEQEMBI clears highly ...

LEQEMBI is indicated for the treatment of ... Monitoring and Dose Management Guidelines Baseline brain MRI and periodic monitoring with MRI are recommended. Enhanced clinical vigilance for ARIA ...

Alzheimer’s disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy ...